Is Clinical Supply the Weakest Link in Your Chain?

Join us for an insightful webinar on tackling the challenges of clinical supply chain management. Learn how technology can optimize demand planning and forecasting, reducing waste, costs, and patient risks.

GET WEBINAR ACCESS

SPEAKER
Benedict Hirth
Global Lead Manager Supply Chain Optimization, Myonex 

Benedict Hirth currently serves as the Global Lead Manager for Supply Chain Optimization at Myonex. In this role, he oversees robust supply plans across the entire trial portfolio, optimizing global and regional strategies for efficiency, cost-effectiveness, and uninterrupted patient supply. Prior to joining Myonex, Benedict was a Senior Manager at ThermoFisher Scientific, where he managed five global teams starting in 2022. He began his pharmaceutical career in 2014 at ThermoFisher as an Associate Project Manager focused on supply chain optimization, advancing through various roles to become a Team Leader in 2020. A trained expert in forecasting and simulation, Benedict holds a master’s degree in biology, specializing in Computational Neuroscience. 

Webinar Abstract Section:

The clinical supply chain is complex, navigating trial designs, sustainability, and evolving regulations, including patient-centric approaches like decentralized trials and direct-to-patient strategies. Benedict Hirth will discuss these dynamics, highlighting the risks associated with poor management such as delayed drug availability, aggressive enrollment targets, and potential commercialization delays. Such challenges can lead to drug shortages, damaging reputation and impacting patient treatment efficacy. 

Hirth will also outline proactive strategies, including risk identification, market observation, and scenario preparedness. He will emphasize leveraging technology and partnering effectively to enhance efficiency and reduce risks.

Watch today and gain valuable insights into advancing your clinical supply chain management practices. 

REGISTER NOW

Learn more about

Delayed drug availability at study start
Results in more aggressive enrollment targets/timelines
Potential delayed commercialization results in profit loss
Drug shortage
Reputation loss at sites 
Additional burden on patients 
Drug sourcing/Out of stock 
Potential impact in treatment efficacy and potential patient loss from clinical trials 
Clinical data impact 
Delayed commercialization 
Proactive supply chain management
Identify potential risks ahead of time and apply mitigation strategies
Observe market situation for commercial drug sourcing
Plan for the best, prepare for the worst
Use technology for demand planning and forecasting
Reduce waste and cost while keeping risk to patients at a minimum

Learn more about

Delayed drug availability at study start
Delayed drug availability at study start
Delayed drug availability at study start
Delayed drug availability at study start
Delayed drug availability at study start
Delayed drug availability at study start
Delayed drug availability at study start
Delayed drug availability at study start
Delayed drug availability at study start
Delayed drug availability at study start
Delayed drug availability at study start
Delayed drug availability at study start
Delayed drug availability at study start
Delayed drug availability at study start
Delayed drug availability at study start
Delayed drug availability at study start